Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Certara Inc (NQ: CERT )

10.25 +0.05 (+0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara Inc

< Previous 1 2 3 4 5 Next >
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies 
From Certara
Via GlobeNewswire
Where Certara Stands With Analysts
Via Benzinga
Macy's, Big Lots, Sprouts Farmers Market And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
9 Analysts Have This to Say About Certara
Within the last quarter, Certara (NASDAQ:CERT) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Certara
Certara (NASDAQ:CERT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency 
From Certara
Via GlobeNewswire
Certara Announces Transition Plan for Chief Financial Officer
From Certara
Via GlobeNewswire
Certara to Participate in the Barclays Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
From Certara
Via GlobeNewswire
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Certara improves software capabilities by expanding into deep learning and data fabric 
From Certara
Via GlobeNewswire
Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity 
From Certara
Via GlobeNewswire
Why Certara's Shares Rose 37.7% This Week
The company, which helps other companies in their drug development, reported strong third-quarter numbers. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Certara Reports Third Quarter 2022 Financial Results
Biosimulation software and services fuel third quarter growth 
From Certara
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Dow Up Triple Digits Ahead Of Busy Week
The Dow Jones Industrial Average is up 212 points midday, continuing Friday's flourish, while the Nasdaq Composite and S&P 500 Index sit more hesitantly in the black. 
Via Talk Markets
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares 
From Certara
Via GlobeNewswire
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Earnings Outlook For Certara
Certara (NASDAQ:CERT) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Certara will report... 
Via Benzinga
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions
The PMDA enters 9th consecutive year of using Certara’s software 
From Certara
Via GlobeNewswire
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
From Certara
Via GlobeNewswire
Where Certara Stands With Analysts
Over the past 3 months, 9 analysts have published their opinion on Certara (NASDAQ:CERT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Jim Cramer Says This Stock Is A 'Great Spec And I Usually Don't Say That,' And Analysts Approve
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Certara, Inc. (NASDAQ: CERT) is not bad and also not losing money. "I think it’s a great spec, and I usually don’t say that," he added. 
Via Benzinga
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
Expert Ratings for Certara
Over the past 3 months, 9 analysts have published their opinion on Certara (NASDAQ:CERT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.